



FDA Provides Feedback on ANAVEX2-73 Alzheimer's Disease Program (Anavex Life Sciences)

Anavex Life Sciences reported FDA feedback following a Type C meeting on its Alzheimer's disease program for ANAVEX2-73 (blarcamesine), with the FDA requesting submission of existing Phase IIb/III data and noting no major safety concerns. The update reflects continued regulatory engagement as the company advances its oral investigational therapy.

[Read the Press Release](#)

Blood-Based Biomarker Study Estimates Population Prevalence of Alzheimer's Neuropathology

A large population-based study in Norway used plasma pTau217 to estimate the prevalence of Alzheimer's disease neuropathological changes in more than 11,000 individuals over 57 years of age. The prevalence increased markedly with age and was detected across dementia, mild cognitive impairment, and cognitively unimpaired groups, suggesting different age-related patterns than previously estimated.

[Read the Study](#)

FDA Accepts and Grants Priority Review to AXS-05 for Alzheimer's Disease Agitation (Axsome Therapeutics)

The FDA accepted Axsome Therapeutics' supplemental NDA for AXS-05 (dextromethorphan-bupropion) for the treatment of Alzheimer's disease agitation and granted Priority Review, with a PDUFA action date of April 30, 2026. The application is supported by multiple Phase 3 trials and addresses a major need, as agitation affects a large proportion of patients with Alzheimer's disease.

[Read the Press Release](#)

CPE Spotlight

To start the new year, this CPE Spotlight offers a reminder of CPE's core service offerings for clients across marketing and medical affairs. While these reflect our core capabilities, our team regularly customizes solutions to meet evolving client needs.

Medical Affairs



- Advisory Boards (In-Person or Virtual)
- KOL Identification and Contracting
- Content Development
- Scientific Platform Development
- MOA Visualization
- Core Slide Decks
- Technical Productions
- MSL Training
- Publications
- Poster Presentations
- Conference Planning & KOL Encounters
- Asynchronous Engagements
- Patient Education

Marketing

- Content Development
- Core Slide Decks
- Virtual or In-Person Advisory Boards
- KOL Engagements
- Technical Productions
- Speaker Bureau Services
- Speaker Training
- Product Theater Planning and Logistics
- Conference Planning (Booth & Logistical Management)
- Launch Preparation
- Publications
- Branding & Visual Aids
- Annual Healthcare Event Production Management



Intentional communication and stakeholder engagement can support AriBio as your pipeline advances through clinical development, including KOL interactions, advisory boards, content development, and strategic marketing initiatives.

We would be pleased to share a tailored capabilities overview, highlighting how CPE can partner with your team and apply our experience in neurology and Alzheimer's.

With appreciation,

Allison Goldberg, MPA
Associate Vice President
CPE Communications
Cell: 917-509-9583
agoldberg@cpeducate.com



When you're ready to explore how the CPE Communications Team can support AriBio, contact Allison at agoldberg@cpeducate.com